Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer

Clin Lung Cancer. 2022 Mar;23(2):e116-e117. doi: 10.1016/j.cllc.2021.12.003. Epub 2021 Dec 10.

Authors

Moto Yaga¹, Takayuki Shiroyama², Haruhiko Hirata¹, Kaori Oya³, Yoshito Takeda¹, Atsushi Kumanogoh¹

Affiliations

¹ Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
² Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan. Electronic address: [email protected].
³ Clinical Laboratory, Osaka University Dental Hospital, Osaka, Japan.

PMID: 34980563
DOI: 10.1016/j.cllc.2021.12.003

No abstract available

Keywords: Immune checkpoint inhibitors; Immune-related pneumonitis; Interstitial lung disease; Lipid-laden macrophage; Respiratory failure.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Carcinoma, Non-Small-Cell Lung / complications
Carcinoma, Non-Small-Cell Lung / drug therapy*
Glucocorticoids / therapeutic use
Humans
Lung Diseases, Interstitial / chemically induced
Lung Neoplasms / complications
Lung Neoplasms / diagnostic imaging*
Pneumonia / chemically induced*
Risk Factors

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Glucocorticoids
pembrolizumab